Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders

doi:10.1016/0165-5728(92)90192-N

Journal of Neuroimmunology

Volume 41, Issue 1, November 1992, Pages 29-34

https://doi.org/10.1016/0165-5728(92)90192-N Get rights and content

Abstract

A substrate conversion assay was used to detect gelatinase activity in the cerebrospinal fluid (CSF) of patients with various neurological disorders. Two main forms of gelatinase with an apparent molecular mass of 65 and 85 kDa, respectively, could be discerned. The high molecular mass gelatinase was detectable only in samples of patients with multiple sclerosis or other inflammatory neurological disorders. A statistically significant correlation was found between the level of the 85-kDa gelatinase and the CSF cytosis. This protease could play a role in the process of demyelination and breakdown of the blood-brain barrier in certain neurological disorders, such as multiple sclerosis.

References (29)

C. Heussen et al.
Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates
Anal. Biochem.
(1980)
M. Lotz et al.
Interleukin-6 induces the synthesis of tissue inhibitor of metalloproteinases-1/erythroid potentiating activity (TIMP-1/EPA)
J. Biol. Chem.
(1991)
A.R. Mackay et al.
Studies on the ability of 65-kDa and 92-kDa tumor cell gelatinases to degrade type IV collagen
J. Biol. Chem.
(1990)
D. Maimone et al.
Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis
J. Neuroimmunol.
(1991)
S. Masure et al.
Human hepatoma cells produced an 85 kDa gelatinase regulated by phorbol 12-myristate 13-acetate
Biochim. Biophys. Acta
(1990)
L.M. Matrisian
Metalloproteinases and their inhibitors in matrix remodeling
Trends Genet.
(1990)
G. Opdenakker et al.
Natural human monocyte gelatinase and its inhibitor
FEBS Lett.
(1991)
T. Sato et al.
Interleukin 6 enhances the production of tissue inhibitor of metalloproteinase (TIMP) but not that of matric metallopreteinase by human fibroblasts
Biochem. Biophys. Res. Commun.
(1990)
E.C. Alvord et al.
Degradation of myelin basic protein by cerebrospinal fluid: preservation of antigenic determinants under physiological conditions
Ann. Neurol.
(1979)
C.F. Brosnan et al.
Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis
Nature
(1980)

W. Cammer et al.

Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination

M.L. Cuzner et al.

Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis

Ann. Neurol.

(1978)

K. Frei et al.

Production of B cell stimulatory factor-2 and interferon-gamma in the central nervous system during viral meningitis and encephalitis

J. Exp. Med.

(1988)

K. Gijbels et al.

Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis

Eur. J. Immunol.

(1990)

Cited by (286)

Three-year follow-up of rheumatoid meningitis with matrix metalloprotease-9 levels in the serum and cerebrospinal fluid as indicators of disease activity: A case report
2024, Journal of Neuroimmunology
Rheumatoid meningitis (RM) is an extra-articular complication of rheumatoid arthritis (RA). Although reports of RM sine arthritis exist, most patients with this presentation were diagnosed with RA within one year of RM onset. There are no established biomarkers reflecting the disease activity of RM. This case report highlights the elevation of matrix metalloprotease (MMP)-9 levels during the acute phase of RM and decline during remission. Additionally, this is the first case report of RA diagnosed three years after the onset of RM. It is important to further validate the utility of MMP-9 and conduct long-term follow-up of RM sine arthritis.
Trichinella spiralis excretory-secretory products downregulate MMP-9 in Dark Agouti rats affected by experimental autoimmune encephalomyelitis
2021, Experimental Parasitology
Matrix metalloproteinases (MMPs), are implicated in the pathogenesis of multiple sclerosis (MS) and in its animal model, experimental autoimmune encephalomyelitis (EAE). Our aim was to investigate whether amelioration of EAE in Dark Agouti (DA) rats, induced by Trichinella spiralis muscle larvae excretory-secretory products (ES L1), could be related to the level and activity of gelatinases, MMP-9 and MMP-2. Serum levels of MMP-9, MMP-2, NGAL/MMP-9, TIMP-1, and cytokines, evaluated by gel-zymography or ELISA, as well as gelatinases and TIMP-1 expression in the spinal cord (SC), were determined in: i) EAE induced, ii) ES L1-treated EAE induced animals. Milder clinical signs in ES L1-treated EAE induced DA rats were accompanied with lower serum levels of MMP-9 and NGAL/MMP-9 complex. However, the correlation between the severity of EAE and the level of serum MMP-9 was found only in the peak of the disease, with MMP-9/TIMP-1 ratio higher in EAE animals without ES L1 treatment. Lower expression of MMP-9 in SC of ES L1-treated, EAE induced rats, correlated with the reduced number of SC infiltrating cells. In SC infiltrates, in the effector and the recovery phase, production of anti-inflammatory cytokines IL-4 and IL-10 was higher in animals treated with ES L1 prior to EAE induction, compared to untreated EAE animals. Reduced expression of MMP-9 in SC tissue, which correlated with the reduced number of infiltrating cells, might be ascribed to regulatory mechanisms, among which is IL-10.
Oxysterols and multiple sclerosis: Physiopathology, evolutive biomarkers and therapeutic strategy
2021, Journal of Steroid Biochemistry and Molecular Biology
Multiple sclerosis is an autoimmune disease that affects the central nervous system. Dysfunction of the immune system leads to lesions that cause motor, sensory, cognitive, visual and/or sphincter disturbances. In the long term, these disorders can progress towards an irreversible handicap. The diagnosis takes time because there are no specific criteria to diagnose multiple sclerosis. To realize the diagnosis, a combination of clinical, biological, and radiological arguments is therefore required. Hence, there is a need to identify multiple sclerosis biomarkers. Some biomarkers target immunity through the detection of oligoclonal bands, the measurement of the IgG index and cytokines. During the physiopathological process, the blood-brain barrier can be broken, and this event can be identified by measuring metalloproteinase activity and diffusion of gadolinium in the brain by magnetic resonance imaging. Markers of demyelination and of astrocyte and microglial activity may also be of interest as well as markers of neuronal damage and mitochondrial status. The measurement of different lipids in the plasma and cerebrospinal fluid can also provide suitable information. These different lipids include fatty acids, fatty acid peroxidation products, phospholipids as well as oxidized derivatives of cholesterol (oxysterols). Oxysterols could constitute new biomarkers providing information on the form of multiple sclerosis, the outcome of the disease and the answer to treatment.
The multifaceted role of metalloproteinases in physiological and pathological conditions in embryonic and adult brains
2017, Progress in Neurobiology
Matrix metalloproteinases (MMPs) are a large family of ubiquitous extracellular endopeptidases, which play important roles in a variety of physiological and pathological conditions, from the embryonic stages throughout adult life. Their extraordinary physiological “success” is due to concomitant broad substrate specificities and strict regulation of their expression, activation and inhibition levels. In recent years, MMPs have gained increasing attention as significant effectors in various aspects of central nervous system (CNS) physiology. Most importantly, they have been recognized as main players in a variety of brain disorders having different etiologies and evolution. A common aspect of these pathologies is the development of acute or chronic neuroinflammation. MMPs play an integral part in determining the result of neuroinflammation, in some cases turning its beneficial outcome into a harmful one. This review summarizes the most relevant studies concerning the physiology of MMPs, highlighting their involvement in both the developing and mature CNS, in long-lasting and acute brain diseases and, finally, in nervous system repair. Recently, a concerted effort has been made in identifying therapeutic strategies for major brain diseases by targeting MMP activities. However, from this revision of the literature appears clear that MMPs have multifaceted functional characteristics, which modulate physiological processes in multiple ways and with multiple consequences. Therefore, when choosing MMPs as possible targets, great care must be taken to evaluate the delicate balance between their activation and inhibition and to determine at which stage of the disease and at what level they become active in order maximize chances of success.
Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation
2017, Drug Discovery Today
Citation Excerpt :
Although several studies demonstrated that alteration of various MMPs contributes to the development of MS, a convergence of data indicate MMP-9 as the key factor involved in different steps of MS pathogenesis (Fig. 3b). During the acute MS phase, MMP-9 levels are elevated in the cerebrospinal fluid (CSF) and are related to magnetic resonance imaging (MRI) activity [34,35]. Liuzzi et al. [36] demonstrated the intrathecal synthesis of MMP-9 and found a significant inverse correlation between MMP-9 and its endogenous inhibitor TIMP-1, indicating that in MS patients the increase in MMP-9 and the decrease in TIMP-1 serum levels could contribute to BBB disruption and T lymphocyte entry into the CNS.
Alterations in matrix metalloproteinase (MMP) expression and activity are recognized as key pathogenetic events in several neurological disorders. This evidence makes MMPs possible therapeutic targets. The search for substances that can inhibit MMPs is moving progressively toward the screening of natural products. In particular, marine bioprospecting could be promising for the discovery of marine natural products with anti-MMP activities. Despite recent advances in this field, the possibility of using marine MMP inhibitors (MMPIs) for the treatment of neuroinflammation is still under-investigated. Here, we review the latest findings in this promising research field and the potential that marine MMPIs can have in the management and treatment of various neurological diseases.
Multiple sclerosis: Association of gelatinase B/matrix metalloproteinase-9 with risk and clinical course the disease
2017, Multiple Sclerosis and Related Disorders
Citation Excerpt :
Despite controversial results (La Russa et al., 2010; Mirowska-Guzel et al., 2009), it is generally accepted that the −1562 C/T polymorphism has no impact on susceptibility to MS (Nischwitz et al., 2015), but its possible influence on disease course is still largely unknown. At protein level, both gelatinase B/MMP-9 increased concentration (Gijbels et al., 1992; Lee et al., 1999) and activity (Avolio et al., 2003; Liuzzi et al., 2002) in serum and in the cerebrospinal fluid (CSF) of MS patients, compared to controls, have been well established. In fact, this MMP has been suggested as a useful marker for the evaluation of the clinical type, disability and severity of MS (Benesova et al., 2009).
Multiple sclerosis (MS) is an autoimmune disease characterized by inflammation and axonal degeneration of the central nervous system and a leading cause of disability in young adults. The matrix metalloproteinases in general and specially gelatinase B/metalloproteinase-9 (MMP-9) plays a role in the pathogenesis of multiple sclerosis.
To investigate the presence of the MMP-9 −1562 C/T polymorphism in a Portuguese population of MS patients and assess its impact in susceptibility and course of the disease. The relation of MMP-9 serum levels with the polymorphism and with clinical and therapeutic factors will also be assessed.
Our study included 355 Caucasian individuals distributed as MS patients (n=169) and controls (n=186). Samples were genotyped for −1562 C/T polymorphism by PCR-RFLP analysis. MMP-9 concentration in serum was analyzed using a commercially available enzyme-linked immunosorbent assay.
A significant increase in T-allele frequency was found in female MS patients, but not in the total patient population. No association between the presence of the polymorphism and disease progression was found. MMP-9 serum concentrations were increased in patients, and although not influenced by the −1562 C/T polymorphism, were modified by INF-beta therapy.
Although we did not find an association of this polymorphism with disease susceptibility or prognosis, MMP-9 appears to be a good therapeutic response marker for multiple sclerosis.

View all citing articles on Scopus

View full text

Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders

Abstract

Anal. Biochem.

J. Biol. Chem.

J. Biol. Chem.

J. Neuroimmunol.

Biochim. Biophys. Acta

Trends Genet.

FEBS Lett.

Biochem. Biophys. Res. Commun.

Degradation of myelin basic protein by cerebrospinal fluid: preservation of antigenic determinants under physiological conditions

Ann. Neurol.

Proteinase inhibitors suppress the development of experimental allergic encephalomyelitis

Nature

Degradation of basic protein in myelin by neutral proteases secreted by stimulated macrophages: A possible mechanism of inflammatory demyelination

Proteolytic enzyme activity of blood leukocytes and cerebrospinal fluid in multiple sclerosis

Ann. Neurol.

Production of B cell stimulatory factor-2 and interferon-gamma in the central nervous system during viral meningitis and encephalitis

J. Exp. Med.

Interleukin 6 production in the central nervous system during experimental autoimmune encephalomyelitis

Eur. J. Immunol.